MXPA05011269A - Derivados de acido ascorbico estabilizados. - Google Patents

Derivados de acido ascorbico estabilizados.

Info

Publication number
MXPA05011269A
MXPA05011269A MXPA05011269A MXPA05011269A MXPA05011269A MX PA05011269 A MXPA05011269 A MX PA05011269A MX PA05011269 A MXPA05011269 A MX PA05011269A MX PA05011269 A MXPA05011269 A MX PA05011269A MX PA05011269 A MXPA05011269 A MX PA05011269A
Authority
MX
Mexico
Prior art keywords
ascorbic acid
group
stabilized derivatives
amino acid
derivatives
Prior art date
Application number
MXPA05011269A
Other languages
English (en)
Inventor
Yury Shapiro
Original Assignee
Tagra Biotechnologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tagra Biotechnologies Ltd filed Critical Tagra Biotechnologies Ltd
Publication of MXPA05011269A publication Critical patent/MXPA05011269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Derivados del acido ascorbico de la formula general I:(ver formula (I)) en donde R1 es un grupo acilo de C2-C22, un grupo aminoacido, o un grupo alquilo de C1-C17; R2 es amonio o un cation metalico; y cada uno de R3 o R4, independientemente, es hidrogeno, un grupo acilo de C2-C22, un residuo de aminoacido, o un grupo alquilo de C1-C17, son mas estables que el acido ascorbico y se pueden usar como una fuente de vitamina C en composiciones farmaceuticas, nutraceuticas y cosmeticas.
MXPA05011269A 2003-04-21 2004-04-21 Derivados de acido ascorbico estabilizados. MXPA05011269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46409703P 2003-04-21 2003-04-21
PCT/IL2004/000343 WO2004094369A2 (en) 2003-04-21 2004-04-21 Stabilized derivatives of ascorbic acid

Publications (1)

Publication Number Publication Date
MXPA05011269A true MXPA05011269A (es) 2006-01-24

Family

ID=33310853

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011269A MXPA05011269A (es) 2003-04-21 2004-04-21 Derivados de acido ascorbico estabilizados.

Country Status (10)

Country Link
US (1) US20070167517A1 (es)
EP (1) EP1620419A4 (es)
JP (1) JP2006524234A (es)
KR (1) KR20060008913A (es)
CN (1) CN1805948A (es)
AU (1) AU2004232556A1 (es)
BR (1) BRPI0409628A (es)
CA (1) CA2523042A1 (es)
MX (1) MXPA05011269A (es)
WO (1) WO2004094369A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266064A1 (en) * 2004-05-29 2005-12-01 Mccarthy Kathryn J Cosmetic compositions and methods
KR100691540B1 (ko) * 2006-06-22 2007-03-12 주식회사 펩트론 펩타이드가 결합된 안정화된 비타민 ｃ 유도체, 이의제조방법 및 이를 함유하는 조성물
FR2904549B1 (fr) * 2006-08-03 2012-12-14 Sederma Sa Composition comprenant de la sarsasapogenine
DE102006037724A1 (de) * 2006-08-11 2008-02-14 Merck Patent Gmbh Verwendung von Ascorbinsäurederivaten zur Funktionalisierung von Matrices
WO2008036238A2 (en) * 2006-09-19 2008-03-27 Wyeth Use of lxr modulators for the prevention and treatment of skin aging
US20080095757A1 (en) * 2006-10-23 2008-04-24 Now Health Group, Inc. Vitamin c compositions
FR2913686B1 (fr) * 2007-03-14 2009-05-01 Oreal Nouveaux composes carbamates de vitamine c, compositions les comprenant, et utilisations
KR101056037B1 (ko) * 2007-07-20 2011-08-10 (주)바이오제닉스 알파-리포일기 함유 아스코르브산 유도체 및 그의 제조방법
FR2946252B1 (fr) * 2009-06-08 2011-07-29 Fabre Pierre Dermo Cosmetique Bis esters d'acide gras insature sur l'acide ascorbique et leurs utilisations cosmetiques
DE102009060543B4 (de) * 2009-12-23 2014-02-06 Axel Muntermann Verfahren zur kosmetischen Hautglättung
CA2803240A1 (en) * 2012-01-18 2013-07-18 Human Matrix Sciences, Llc Sodium ascorbate stimulation of elastogenesis
WO2015048121A1 (en) * 2013-09-25 2015-04-02 University Of Florida Research Foundation, Inc. Vitamin c prodrugs and uses thereof
CN103655223B (zh) * 2013-11-14 2016-06-29 陕西东大生化科技有限责任公司 一种具有预防和治疗痤疮功效的制剂及其应用
CN103896891A (zh) * 2014-03-25 2014-07-02 李玉成 抗坏血酸锂及其制备方法
WO2020145790A1 (ko) * 2019-01-11 2020-07-16 경북대학교 산학협력단 히알루론산 나노 입자를 합성하는 방법 및 이 방법으로 제조된 히알루론산 나노 입자
CN110467689A (zh) * 2019-09-09 2019-11-19 山东众山生物科技有限公司 一种透明质酸衍生物及其制备方法
CN113527537B (zh) * 2021-07-14 2022-04-08 润辉生物技术（威海）有限公司 一种左旋维生素c透明质酸酯衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852614B (en) * 1985-05-17 1986-10-09 Takeda Chemical Industries, Ltd. Ascorbic acid ethers and their production
CN1093360A (zh) * 1992-10-02 1994-10-12 武田药品工业株式会社 2-o-烷基抗坏血酸的锂盐
FR2715156B1 (fr) * 1994-01-20 1996-03-01 Oreal Mono-esters d'acide cinnamique ou de ses dérivés et de vitamine C, leur procédé de préparation et leur utilisation comme anti-oxydants dans des compositions cosmétiques, pharmaceutiques ou alimentaires.
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
DE19750526A1 (de) * 1997-11-14 1999-05-20 Basf Ag Ascorbinsäurederivate enthaltende kosmetische und pharmazeutische Zubereitungen
DE19750528A1 (de) * 1997-11-14 1999-05-20 Basf Ag Ascorbylsorbate
JP4981198B2 (ja) * 1998-03-31 2012-07-18 格 山本 グリコシル−ｌ−アスコルビン酸のアシル化誘導体
FR2807320B1 (fr) * 2000-04-10 2002-05-24 Oreal Utilisation de derives d'acide ascorbique pour augmenter la synthese des creramides epidermiques
ES2261458T3 (es) * 2001-07-26 2006-11-16 Tagra Biotechnologies Ltd Derivados estabilizados del aciddo ascorbico 3-fosfato.
ZA200304712B (en) * 2001-08-24 2004-07-12 Matthias Rath Novel ascorbic acid compounds, methods of synthesis and application use thereof.
JP2004051535A (ja) * 2002-07-19 2004-02-19 Lion Corp 口腔用組成物

Also Published As

Publication number Publication date
AU2004232556A1 (en) 2004-11-04
KR20060008913A (ko) 2006-01-27
CN1805948A (zh) 2006-07-19
WO2004094369A3 (en) 2005-02-03
US20070167517A1 (en) 2007-07-19
EP1620419A2 (en) 2006-02-01
EP1620419A4 (en) 2008-07-23
CA2523042A1 (en) 2004-11-04
WO2004094369A2 (en) 2004-11-04
BRPI0409628A (pt) 2006-04-25
JP2006524234A (ja) 2006-10-26

Similar Documents

Publication Publication Date Title
MXPA05011269A (es) Derivados de acido ascorbico estabilizados.
PL1625150T3 (pl) Tripeptydy i ich pochodne do stosowania w kosmetyce w celu poprawy struktury skóry
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MXPA03007249A (es) Compuestos triazolo como inhibidores de mmp.
BG106013A (en) New compounds and compositions as protease inhibitors
GB0114286D0 (en) Nucleoside Derivatives
TW200621729A (en) Pyrimidine derivatives
MY144209A (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200616976A (en) Pyrimidine derivatives
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
DE60305724D1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
MY145464A (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MXPA04000577A (es) Derivados de dolastatina 10.
MXPA03009548A (es) Arilsulfonamidas como agentes antivirales.
TW200730510A (en) Chroman compounds
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
MX2009004006A (es) Derivados de indol novedosos, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
HK1090062A1 (en) Colchicoside analogues
MXPA05012300A (es) Derivados de benzotiofeno de sulfamato como inhibidores de sulfatasa esteroidea.
HUP0301000A2 (hu) 2-Aminotiazolin-származékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk NO-szintáz inhibitorokként
RS20050954A (en) Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions